Policy

Uptake Barriers Will Deter Future Competitors From Investing in Biosimilars, Julie Reed Warns

March 21st 2023

By Skylar Jeremias

At the Festival of Biologics, Juliana (Julie) Reed, executive director of the Biosimilars Forum, warned that without changes to encourage biosimilar uptake, companies will begin to ask the big question: Are biosimilars worth investing in?

How Community Oncologists Can Break Down Biosimilar Adoption Barriers

March 19th 2023

By Skylar Jeremias

Podcast

On this episode of Not So Different, Mark Guyot, senior director of unity provider engagement at McKesson, gives an overview of McKesson’s real-world analysis of community oncology practices and their use of biosimilars and offers advice on overcoming adoption barriers and expanding education efforts.

Researchers Recommend Improvements for China’s Biosimilar Regulatory Policies

March 16th 2023

By Skylar Jeremias

Article

In an article published in Frontiers in Pharmacology, researchers made recommendations to improve the biosimilar regulatory system and refine biosimilar guidelines in China.

CVS Predicts Interchangeability Won’t Drive Adalimumab Biosimilar Adoption

March 15th 2023

By Skylar Jeremias

Article

In a report from CVS Health, interchangeability will not be a primary factor in driving the adoption of adalimumab biosimilars referencing Humira, contradicting predictions from other sources that believe the designation will impact prescribing habits.

Biorationality: A Dr Sarfaraz Niazi Column—A New Perspective on Biosimilars' Role Within Big Pharma

March 13th 2023

By Sarfaraz K. Niazi, PhD

Article

Sarfaraz K. Niazi, PhD, explained why Indian manufacturers aren’t bringing biosimilars to the United States and how FDA policies and procedures discourage global companies from pursuing US market entry.

IQVIA's Michael Kleinrock Shares Why Smaller Manufacturers Are Investing in Biosimilar Development

March 12th 2023

By Skylar Jeremias

Video

Better familiarity with biosimilars is enabling government agencies to reevaluate their approval requirements and encouraging smaller manufacturers to invest in biosimilar development, said Michael Kleinrock, lead research director for the IQVIA Institute for Human Data Science.

Policy Recommendations for Improving Biosimilar Uptake in Belgium

March 11th 2023

By Deana Ferreri, PhD

Article

Increasing the use of biosimilars in Belgium will require realigning financial incentives and providing more information to medical professionals, according to authors of a study that proposed policy recommendations.

White Paper Argues Increased Competition Will Improve Biosimilar Uptake, Savings

March 8th 2023

By Skylar Jeremias

Article

A white paper touting biosimilar successes in the United States reasoned that increased market competition will help improve utilization rates, generate substantial savings, and encourage payers to cover biosimilars.

Dr Ivo Abraham Column: The 2022 WHO Biosimilar Guidelines—Loosening the Reins or Changing the Track? Part 2

March 7th 2023

By Ivo Abraham, PhD

Article

In part 2 of this 2-part series, Ivo Abraham, PhD, chief scientist of Matrix45 and a professor at the University of Arizona, continued to examine guidelines from the World Health Organization (WHO) and how they view interchangeability and animal study requirements.

Lilly Plans to Launch Insulin Biosimilar at 78% Discount to Lantus

March 2nd 2023

By Skylar Jeremias

Article

As Eli Lilly and Company announces that it will slash prices for its insulin products and cap out-of-pocket costs for insulin, the company shared that it will launch its interchangeable insulin biosimilar, Rezvoglar, at a 78% discount to the originator (Lantus).